ClinicalTrials.gov
public full text
Public Domain
Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis
Current treatment of tuberculosis (TB) requires patients to take four drugs for 8 weeks and then two drugs for 4 months. New drug regimens that are shorter and effective against drug-resistant TB are needed. This study will evaluate whether using the drug moxifloxacin (MOX) in place of ethambutol (EMB) during the first 8 weeks of treatment will effectively treat TB.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Shortening Treatment by Advancing Novel Drugs#1153608
- Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis#841307
- Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis#1095481
- Antigen heterogeneity in the development and clinical validation of a multiplexed urine test for tuberculosis.#13590
- Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas#812861
Record · ID 1163372
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive